熱門資訊> 正文
Foghorn Therapeutics任命Ryan Maynard为首席财务官
2026-02-23 20:27
- Foghorn Therapeutics (FHTX) said on Monday that Ryan Maynard will join the clinical-stage biotech as CFO effective Feb. 23, 2026.
- Maynard brings over 25 years of executive experience in biopharma and healthcare technology, has raised more than $1 billion in public and private financings, and most recently served as CFO of Cara Therapeutics. He currently serves on the board of Iovance Biotherapeutics.
- Shares -1.72%.
More on Foghorn Therapeutics
- Seeking Alpha’s Quant Rating on Foghorn Therapeutics
- Historical earnings data for Foghorn Therapeutics
- Financial information for Foghorn Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
